Q-omics provides the consensus-scored MSS51 profile across patient tissues and cancer cell-line models. MSS51 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MSS51 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, MSS51 RNA expression shows 19,432 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LIHC, and UVM as cancer lineages where MSS51 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSS51 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSS51 survival associations across molecular data types. MSS51 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSS51 RNA expression–survival associations across cancer types. High MSS51 expression shows unfavorable associations in KIRC, LIHC, ACC and COAD, but favorable associations in SKCM and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MSS51 RNA expression.
This table summarizes MSS51 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MSS51. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSS51 shows lower tumor expression in BRCA and KICH and higher tumor expression in LIHC, CHOL and KIRC. The LIHC box plot shows higher MSS51 RNA expression in tumor versus normal tissue (log2 FC = +0.565, t-test p < 0.001).
This table shows molecular features associated with MSS51 in patient tissues and cancer cell lines. In patient samples, MSS51 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MSS51 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
